FDA OK's Vanda’s Hetlioz for sleep disorder in blind
This article was originally published in Scrip
Executive Summary
Shares of Vanda Pharmaceuticals gained $2.53, or about 20%, on 31 January after the FDA approved the company’s drug Hetlioz (tasimelteon) as circadian regulator to treat non-24-Hour (non-24), a rare sleep-wake disorder, in patients with total blindness.
You may also be interested in...
Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen
The latest drug development news and highlights from our US FDA Performance Tracker.
Vanda Not Ready To Give Up On Jet Lag Indication For Hetlioz Despite CRL
Complete response letter follows July deficiencies letter that made approval seem highly unlikely. Vanda called the setback perplexing and said it plans to continue working to get jet lag disorder added to the Hetlioz label.
Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
The latest drug development news and highlights from our US FDA Performance Tracker.